ARQT Share Price Performance
US$23.56
8.58 (57.28%)
32.2% undervalued intrinsic discount
US$34.75
Fair Value
Price US$23.56
AnalystConsensusTarget US$34.75
Coward_Nutlick US$39.99
Fair ValueUS$34.75
Share Pricen/a
Arcutis Biotherapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 61 Fair Values set on narratives written by author
ARQT Community Narratives
AN
Fair Value US$34.75 32.2% undervalued intrinsic discount
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
0users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
CO
Fair Value US$39.99 41.1% undervalued intrinsic discount
Very Bullish
4users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Very Bullish
It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.Read more
560
users have viewed this narrative4users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
CO
US$39.99
41.1% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2030
US$55.82
Analysts Cite Strong Sales and Pipeline as Arcutis Biotherapeutics Price Target Rises
Key Takeaways Expansion of ZORYVE indications and partnerships targets underserved populations, supporting sustained revenue and margin improvement through diversification and operating leverage. Demand for innovative non-steroidal treatments and ongoing R&D investments enhance long-term growth, portfolio expansion, and market share amid favorable demographic trends.Read more
299
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
US$34.75
32.2% undervalued intrinsic discount
Fair Value
Profit Margin
34.01%
Future PE
22.31x
Price in 2029
US$42.51
Trending Discussion
Recently Updated Narratives
CO
Very Bullish
Fair Value: US$39.99 41.1% undervalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
AN
ARQT: Strong Q4 Execution And Higher 2026 Guidance Will Support Confidence
Fair Value: US$34.75 32.2% undervalued intrinsic discount
32 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Arcutis Biotherapeutics, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.13
- 90.24%
- -4.29%
- 57.5%
About ARQT
- Founded
- 2016
- Employees
- 354
- CEO
- WebsiteView website
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company’s lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
